CLINICAL DEVELOPMENT STRATEGY

We are developing medicines to selectively eliminate senescent cells, called senolytic medicines. Our initial focus is on delivering localized therapy in osteoarthritis, ophthalmology and pulmonary disease. Beyond cellular senescence, we are uncovering additional underlying mechanisms that contribute to age-related diseases including:

  • Mitochondrial dysfunction
  • Loss of circulating youth factors
PIPELINE
PIPELINE
LEAD PRODUCT CANDIDATES

UBX0101 is designed to treat musculoskeletal disease with an initial focus on osteoarthritis of the knee. UBX0101 is a potent senolytic small molecule inhibitor of the MDM2/p53 protein interaction. Disruption of this protein interaction can trigger the elimination of senescent cells. An Investigational New Drug (IND) application was cleared by the U.S. FDA, and a Phase 1 clinical trial in osteoarthritis of the knee was initiated in the second quarter of 2018. Initial results from the Phase 1 study are expected to be available in the second quarter of 2019.

 

 

 

UBX1967 is being evaluated for the potential treatment of age-related diseases of the eye, including age-related macular degeneration, diabetic macular edema and proliferative diabetic retinopathy. UBX1967, a potent senolytic small molecule inhibitor of particular members of the Bcl-2 family of apoptosis regulatory proteins, targets proteins senescent cells rely on for survival. UNITY plans to submit an IND application in the second half of 2019 for UBX1967. UNITY entered into a license agreement with Ascentage Pharma Group Corp Limited “Ascentage Pharma” in January 2019 granting UNITY exclusive worldwide development and commercialization rights and non-exclusive manufacturing rights outside of Greater China for UBX1967 in all non-oncology indications. Inside Greater China, UNITY is obligated to commercialize UBX1967 through a joint venture with Ascentage Pharma.

CLINICAL TRIALS
A Safety and Tolerability Study of UBX0101 in Patients with Osteoarthritis of the Knee

Summary: This double-blind, randomized, placebo-controlled Phase 1 study is evaluating the safety, tolerability and pharmacokinetics of a single intra-articular injection of UBX0101 into the femoro-tibial joint of patients diagnosed with moderate to severe painful osteoarthritis of the knee.

Status: Recruiting patients

For patients or physicians interested in learning about eligibility criteria for the trial, please visit clincialtrials.gov.